Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).
GlaxoSmithKline has announced the repurchase of 348,430 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on June 9, 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders. The shares will be held as treasury shares, and following this purchase, GSK holds 219,571,109 ordinary shares in treasury. The buyback program is expected to enhance shareholder value and optimize the company’s financial position.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GSK’s overall stock score reflects strong technical momentum and positive corporate events, despite concerns over valuation and leverage risks. The company’s strategic focus on specialty medicines and robust earnings outlook further support the investment case.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a global healthcare company engaged in the development, manufacturing, and marketing of pharmaceuticals, vaccines, and consumer healthcare products. The company focuses on improving the quality of human life by enabling people to do more, feel better, and live longer.
Average Trading Volume: 10,052,714
Technical Sentiment Signal: Strong Buy
Current Market Cap: £61.32B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.